Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2386 to 2400 of 9128 results

  1. Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies [TSID10765]

    Awaiting development Reference number: GID-TA11050 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]

    Awaiting development Reference number: GID-TA11087 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]

    Awaiting development Reference number: GID-TA11162 Expected publication date:  28 July 2027

    Technology appraisal guidance
    Awaiting development

  4. Shared decision-making: practical guidance for health and social care professionals

    Awaiting development Reference number: GID-QS10097 Expected publication date: TBC

    Quality standard
    Awaiting development

  5. Advocacy services for adults with health and social care needs

    Awaiting development Reference number: GID-QS10145 Expected publication date: TBC

    Quality standard
    Awaiting development

  6. Safeguarding adults in care homes

    Awaiting development Reference number: GID-QS10147 Expected publication date: TBC

    Quality standard
    Awaiting development

  7. Supporting independent living and preventing isolation in adults of working age with social care needs

    Awaiting development Reference number: GID-QS10149 Expected publication date: TBC

    Quality standard
    Awaiting development

  8. Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191]

    Awaiting development Reference number: GID-TA11746 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]

    In development Reference number: GID-TA11780 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Zasocitinib for treating moderate to severe plaque psoriasis [ID6700]

    Awaiting development Reference number: GID-TA11926 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment

    Awaiting development Reference number: GID-HTG10389 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  12. Adrenal dysfunction

    Awaiting development Reference number: GID-QS10038 Expected publication date: TBC

    Quality standard
    Awaiting development

  13. Semaglutide for treating type 2 diabetes [ID1450]

    Awaiting development Reference number: GID-TA10438 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Dulaglutide for treating type 2 diabetes [ID1451]

    Awaiting development Reference number: GID-TA10439 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Sotagliflozin for treating type 2 diabetes [ID1657]

    Awaiting development Reference number: GID-TA10665 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development